Idorsia Advances Lupus Drug Into Phase III Despite Mid-Stage Fail
Phase IIb Study Of Cenerimod Not Statistically Significant
Executive Summary
The Swiss biotech is confident its S1P1 receptor modulator can be an effective treatment for lupus but the move into late-stage studies has raised some eyebrows.
You may also be interested in...
AstraZeneca To Challenge GSK After Clinching Lupus Drug Approval
Fears that US regulators would take issue with AstraZeneca's decision to change the endpoints of a second pivotal trial for anifrolumab were unfounded and the first-in-class type I interferon inhibitor is the first new treatment for systemic lupus erythematosus in more than 10 years.
Crunch Time For Idorsia Insomnia Therapy As Reviews Begin
The US FDA has accepted the Swiss biotech's "huge" NDA file for daridorexant which the company hopes will be more successful on the insomnia market than other DORA sleep treatments such as Merck & Co's Belsomra.
Sanofi Bags EU Approvals But Fumes At Regulator
Although Nexviadyme has been approved, the French group is still unhappy about the EMA's view that the Pompe disease therapy should not be classified as a new active substance.